News
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback